about
Hematopoietic stem cell transplantation: a global perspectivePatterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemiaImproved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trialLong-term survival data from a phase 3 study of Filgrastim as an adjunct to chemotherapy in adults with de novo acute myeloid leukemia.Atypical retinal microvasculopathy after bone marrow transplantation.Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia.A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trialPrior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia--a randomized, placebo-controlled, double-blind safety and efficA no-prophylaxis platelet-transfusion strategy for hematologic cancers.Allogeneic hematopoietic cell transplant for prolymphocytic leukemia.The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remissionSibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapseImpact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.Allogeneic hematopoietic stem cell donation-standardized assessment of donor outcome data: a consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT).Abnormal cervical cytology in bone marrow transplant recipients.Haemopoietic stem cell transplantation in Australia and New Zealand, 1992-2001: progress report from the Australasian Bone Marrow Transplant Recipient Registry.The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation.Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections.Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.Staged autologous peripheral blood progenitor cell transplantation for Ewing sarcoma and rhabdomyosarcoma.The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis?Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation ResearchPolymorphism in human cytomegalovirus UL40 impacts on recognition of human leukocyte antigen-E (HLA-E) by natural killer cells.Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study.Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment.Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy.Enzyme replacement therapy "drug holiday": results from an unexpected shortage of an orphan drug supply in Australia.Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011. Australian Consensus Guidelines 2011 Steering Committee.Design issues in a randomized controlled trial of a pre-emptive versus empiric antifungal strategy for invasive aspergillosis in patients with high-risk hematologic malignancies.How we mobilize haemopoietic stem cells.Hepatitis B serological changes following allogeneic bone marrow transplantation.Disseminated toxoplasmosis after allogeneic stem cell transplantation in a seronegative recipient.Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial.Acute myeloid leukaemia relapsing after allogeneic haematopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse.Pre-transplant ferritin, albumin and haemoglobin are predictive of survival outcome independent of disease risk index following allogeneic stem cell transplantation.A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment.An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009.
P50
Q24624697-A0CE1EAA-AAEF-44EF-9B44-C43744ACAE76Q28191301-D0C231CB-A524-4CFF-9C0C-3823C93BA42DQ28303488-42C0C613-93B1-48F0-9C59-99CA03AC47F8Q31030133-2468C8D6-4535-4A46-AF74-F3C703F13DF6Q31968982-5524078F-FF7B-4AAA-9A85-6619E64AE152Q33341143-A9484796-F706-412F-8177-EC52EE722949Q33346999-2A00B835-31CD-4131-820E-660EBA0BA9BAQ33350688-78061DC4-049E-4E03-B10C-23488070293FQ33357084-D68ABB43-D63E-401F-8041-7CC475ECF28EQ33407550-DE925D8F-203F-4EB3-80C1-8DF61CED63DCQ33729489-CC47C14A-C460-45BB-8575-37E4B35978E1Q34033852-3D8F8ED3-F3EC-4176-90FE-FC72F00D08F4Q34087133-96FDF728-AEA9-49DA-B874-36FDE4AFAE37Q34198055-0349F017-A529-475E-ACF3-F5AA34638092Q34330585-ECC57B1B-2F68-4EE5-AC56-50643E0BA2BDQ34380742-70157402-DA11-4709-B3DC-CB808E842A3EQ34387503-F28392C3-2C91-4CE1-8642-92C1FB4EC637Q34567835-1D18DC06-DE0B-4651-A633-B1E066FD9D48Q34621964-93CE9E17-2F53-41C8-99D9-D6D31ECAF46AQ35746695-6832366F-C3EA-435C-B4FC-F1FD5A3DF4C6Q35757247-F42FFA06-D9D2-4C6B-AAE5-1EDC32C9BC38Q35843945-3DC7668E-5693-4F39-BB8A-58215797FFEFQ36268587-D8EC25A1-7938-44AA-BAAC-5B88DED6D369Q36579065-54DEFD55-1C82-438F-9BEA-8D46C611C24FQ36708679-2D1A698A-741C-4874-821E-6E28005B6D37Q37060673-7674559C-B63A-4BA9-91AC-5117DCC7CA39Q37394305-8CBB2773-2243-4ACD-A7B9-1D4C0A52596EQ37497977-757E9130-CAE8-49A8-B6CE-4743F52C435EQ37761181-C8A9FCD6-A5CD-4918-81EE-1813D44498A3Q37777750-D066EBC4-28FD-409F-A97B-A846BD4D5421Q37832773-CE3AFFA7-95FB-42BA-BDD4-40B210D30D6FQ37833638-31C75739-4BCE-4BB6-B0A6-8F2890411C1DQ37914921-B177B0C3-E60E-4366-8FB5-99924A6AF539Q38025445-3E8D7D19-002E-4689-8BA8-F3BE8C96B350Q38070926-4DF25837-485B-47E8-B516-8431B3A7D5C3Q38103680-F16F9D9F-5589-43BB-AF13-7D6947522CA4Q38719328-D392AFDA-D21D-460E-8462-0F4C3E6C591EQ40201370-DBB461C1-6C29-4751-97B3-ACE9A4175311Q40304299-E94F5412-DC08-4074-BF3C-6015FBFC2247Q40335966-6820CB37-A7BC-4552-A442-6A652EB9FBF6
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jeff Szer
@ast
Jeff Szer
@en
Jeff Szer
@es
Jeff Szer
@nl
Jeff Szer
@sl
type
label
Jeff Szer
@ast
Jeff Szer
@en
Jeff Szer
@es
Jeff Szer
@nl
Jeff Szer
@sl
prefLabel
Jeff Szer
@ast
Jeff Szer
@en
Jeff Szer
@es
Jeff Szer
@nl
Jeff Szer
@sl
P106
P1153
7006053620
P21
P31
P496
0000-0001-6783-2301